Literature DB >> 8142838

Cancer of the prostate.

D P Dearnaley1.   

Abstract

Prostate cancer presents a growing health problem in Western societies as longevity increases. It is characteristically a disease of elderly men associated with the development of osteoblastic bone metastases and initial hormone responsiveness to androgen deprivation. Previously regarded as a Cinderella of cancers, there is currently more controversy concerning the detection and management of both localised and metastatic disease than for any other common malignancy. A balance needs to be drawn between the potential gains of more aggressive management and the disadvantages in terms of increased treatment side effects and cost, taking into account both the natural course of the disease and the life expectancy of patients.

Entities:  

Mesh:

Year:  1994        PMID: 8142838      PMCID: PMC2539670          DOI: 10.1136/bmj.308.6931.780

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  25 in total

1.  Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results.

Authors:  D F Paulson; J W Moul; P J Walther
Journal:  J Urol       Date:  1990-11       Impact factor: 7.450

2.  More on the Uro-Oncology Research Group report of radical surgery vs. radiotherapy for adenocarcinoma of the prostate.

Authors:  G E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-05       Impact factor: 7.038

3.  Total prostatectomy for clinically localized prostatic cancer: long-term results.

Authors:  R P Gibbons; R J Correa; G E Brannen; R M Weissman
Journal:  J Urol       Date:  1989-03       Impact factor: 7.450

4.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

5.  Cancer statistics, 1989.

Authors:  E Silverberg; J A Lubera
Journal:  CA Cancer J Clin       Date:  1989 Jan-Feb       Impact factor: 508.702

6.  Leuprolide with and without flutamide in advanced prostate cancer.

Authors:  E D Crawford; B A Blumenstein; P J Goodman; M A Davis; M A Eisenberger; D G McLeod; J T Spaulding; R Benson; F A Dorr
Journal:  Cancer       Date:  1990-09-01       Impact factor: 6.860

7.  Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation.

Authors:  G K Zagars; A C von Eschenbach; D E Johnson; M J Oswald
Journal:  Cancer       Date:  1987-10-01       Impact factor: 6.860

Review 8.  Epidemiology of prostate cancer.

Authors:  A W Meikle; J A Smith
Journal:  Urol Clin North Am       Date:  1990-11       Impact factor: 2.241

9.  Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial.

Authors:  M D Rifkin; E A Zerhouni; C A Gatsonis; L E Quint; D M Paushter; J I Epstein; U Hamper; P C Walsh; B J McNeil
Journal:  N Engl J Med       Date:  1990-09-06       Impact factor: 91.245

10.  Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate.

Authors:  C A Perez; D Garcia; J R Simpson; F Zivnuska; M A Lockett
Journal:  Radiother Oncol       Date:  1989-09       Impact factor: 6.280

View more
  13 in total

1.  Detection of prostate cancer.

Authors:  F H Schröder
Journal:  BMJ       Date:  1995-01-21

Review 2.  Screening for prostate cancer. Implications for drug therapy.

Authors:  R H Harwood
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

Review 3.  Bicalutamide in advanced prostate cancer. A review.

Authors:  K L Goa; C M Spencer
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

4.  An audit of the investigation and treatment of localised prostatic cancer in the south west region.

Authors:  R N Lodge
Journal:  Ann R Coll Surg Engl       Date:  1999-03       Impact factor: 1.891

5.  Sulfotransferase 1A1 Arg(213)His polymorphism and prostate cancer risk.

Authors:  Serdal Arslan; Yavuz Silig; Hatice Pinarbasi
Journal:  Exp Ther Med       Date:  2011-08-12       Impact factor: 2.447

6.  A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.

Authors:  J M O'Sullivan; A R Norman; V R McCready; G Flux; F M Buffa; B Johnson; J Coffey; G Cook; J Treleaven; A Horwich; R A Huddart; C C Parker; D P Dearnaley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-30       Impact factor: 9.236

Review 7.  Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.

Authors:  L B Barradell; D Faulds
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

Review 8.  Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population.

Authors:  Scott M Gilbert; Mitchell C Benson; James M McKiernan
Journal:  Curr Urol Rep       Date:  2002-06       Impact factor: 3.092

Review 9.  Screening for ovarian, prostatic, and testicular cancers.

Authors:  J Austoker
Journal:  BMJ       Date:  1994-07-30

10.  Controversies in the management of advanced prostate cancer.

Authors:  C J Tyrrell
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.